Roche Pharma seeking EUA from India for its COVID-19 antibody cocktail
Category: #headlines |   By Pankaj Singh |   Date: 2021-04-30  | 
  • Share
  • Twitter
  • Facebook
  • LinkedIn

Roche Pharma seeking EUA from India for its COVID-19 antibody cocktail

Swiss multinational drug marker Roche Pharma recently announced that it is working with the Indian drug regulator to fast-track an emergency use authorization (EUA) of its investigational antibody cocktail Imdevimab and Casirivimab in India.

It is worth noting here that Roche Pharma has applied for a similar approval in the European Union and the United States. Roche claims that an emergency use authorization in India would allow the import of globally manufactured drugs to India as soon as possible.

The company added that is working promptly to expand manufacturing capacity and supply by upscaling its production network and building ties with external partners to maximize production of Tocilizumab (Actemra) at all possible site to increase its availability.

Roche cited that there is a magnified demand for Tocilizumab as the Covid-19 cases continue to surge across the nation. The company as a whole is addressing this grave situation by bringing in supplies over this and the coming weeks, however, worries that the current requirements may far surpass the supplies that will be provided, it added.

For the record, Tocilizumab is considered vital for patients who are moderately affected with Covid-19 and have rising oxygen requirements as time passes or in mechanically ventilated patients who aren’t showing any signs of improvements despite the utilization of steroids.

The drug, which is to be administered in two doses, is produced by Roche while Cipla looks after its and import and distribution in India. A few weeks earlier, this drug went out of stock in the nation due to its massive demand emerging from the steep incline of Covid-19 cases throughout April.

Given the growing necessity of minimizing hospitalization and relieving healthcare from the burgeoning pressure, neutralizing antibody cocktails can play a major role, particularly for the treatment of high-risk patients before their health condition worsens, cited the Swiss giant.

Source Credits –

https://www.moneycontrol.com/news/business/rbi-announces-special-omos-of-rs-10000-crore-each-on-may-6-6831851.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with...

Read More

More News By Pankaj Singh

Greywing launches Crew Change to support shipping companies amid pandemic
Greywing launches Crew Change to support shipping companies amid pandemic
By Pankaj Singh

Maritime operations automation platform Greywing has recently launched Crew Change, a solution to assist shipping companies in managing testing, isolation, and other Covid-19 related regulations for their crew members. Crew Change uses data from a g...

Mamaearth secures Sofina-led USD 50 Mn funding at USD 730 Mn valuation
Mamaearth secures Sofina-led USD 50 Mn funding at USD 730 Mn valuation
By Pankaj Singh

Popular new-age D2C (direct-to-consumer) personal care brand Mamaearth has reportedly raised USD 50 million in a funding round led by Belgian investment fund Sofina, valuing the company at USD 730 million. The round saw participation from existing i...

Porsche, BASF partner to develop high-performing lithium-ion batteries
Porsche, BASF partner to develop high-performing lithium-ion batteries
By Pankaj Singh

Porsche AG has reportedly partnered with BASF to develop the next generation of lithium-ion batteries, which would be used in future Porsche electric vehicles worldwide. Cellforce Group, a joint venture between Customcells and Porsche, chose BASF as ...